ProShare Advisors
RPRX

ProShare Advisors’s Repros Therapeutics Inc. RPRX Stock Holding History

ProShare Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-11,255
Closed -$195K – 2467
2014
Q2 		$195K Sell
11,255
-11,978
-52% -$195K ﹤0.01% 2184
2014
Q1 		$412K Buy
+23,233
New +$450K 0.01% 2018
2013
Q4 		– Sell
-14,502
Closed -$389K – 2559
2013
Q3 		$389K Buy
14,502
+2,364
+19% +$50.7K 0.01% 1678
2013
Q2 		$224K Buy
+12,138
New +$214K ﹤0.01% 1951

Other funds holding RPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DCM
Destrier Capital Management New York $144M AUM 7.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

ProShare Advisors's RPRX Position: Q3 2014 in Review

ProShare Advisors sold out of Repros Therapeutics Inc. (RPRX) in Q3 2014, closing a stake of 11,255 shares — an estimated $195K sold.

ProShare Advisors first reported a position in RPRX in Q2 2013 and held it in 4 quarters. The position peaked at $412K in Q1 2014. 75 funds tracked by Wall St. Rank hold RPRX as of Q3 2014.

  • ProShare Advisors reported no remaining Repros Therapeutics Inc. position as of Q3 2014 after selling out during the quarter.
  • ProShare Advisors sold 11,255 Repros Therapeutics Inc. shares in Q3 2014, an estimated $195K.
  • ProShare Advisors first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 4 quarters.
  • ProShare Advisors's Repros Therapeutics Inc. position peaked at $412K in Q1 2014.
  • 75 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2014.

Based on ProShare Advisors's 13F filing for Q3 2014, filed 6 Nov 2014.